Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 placebo-controlled study of subcutaneous daxdilimab in primary discoid lupus erythematosus
MOH_2024-01-29_013225Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daxdilimab in discoid lupus erythematosus (DLE) (3 arms), sponsored by Horizon Therapeutics. Started Jan 2024; status: completed.
02
Drugs
daxdilimab
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on MOH_2024-01-29_013225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-29_013225.